Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group.
Guilhot
F
F
Département d'Hématologie et Oncologie Médicale, CHU La Milétrie, Poitiers, France.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy*; D008297:Male; D015337:Multicenter Studies as Topic; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic
D016898:Interferon-alpha; D003561:Cytarabine